D.E. Shaw & Co’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-271,291
| Closed | -$46.7M | – | 5914 |
|
|
2021
Q3 | $46.7M | Buy |
271,291
+201,795
| +290% | +$26.4M | 0.04% | 565 |
|
|
2021
Q2 | $8.72M | Sell |
69,496
-3,679
| -5% | -$464K | 0.01% | 1608 |
|
|
2021
Q1 | $9.92M | Buy |
73,175
+11,226
| +18% | +$1.45M | 0.01% | 1358 |
|
|
2020
Q4 | $7.93M | Sell |
61,949
-47,773
| -44% | -$5.6M | 0.01% | 1523 |
|
|
2020
Q3 | $12.3M | Sell |
109,722
-34,964
| -24% | -$3.48M | 0.01% | 1104 |
|
|
2020
Q2 | $13.8M | Sell |
144,686
-74,180
| -34% | -$7.15M | 0.02% | 1004 |
|
|
2020
Q1 | $19.7M | Buy |
+218,866
| New | +$17M | 0.03% | 630 |
|
|
2018
Q4 | – | Sell |
-10,811
| Closed | -$619K | – | 4094 |
|
|
2018
Q3 | $619K | Sell |
10,811
-471
| -4% | -$23.1K | ﹤0.01% | 2988 |
|
|
2018
Q2 | $547K | Buy |
+11,282
| New | +$411K | ﹤0.01% | 3063 |
|
|
2016
Q3 | – | Sell |
-35,205
| Closed | -$1.2M | – | 3627 |
|
|
2016
Q2 | $1.2M | Sell |
35,205
-653
| -2% | -$21.2K | ﹤0.01% | 2301 |
|
|
2016
Q1 | $946K | Sell |
35,858
-4,582
| -11% | -$133K | ﹤0.01% | 2394 |
|
|
2015
Q4 | $1.97M | Buy |
+40,440
| New | +$1.46M | ﹤0.01% | 2141 |
|
|
2015
Q3 | – | Sell |
-29,190
| Closed | -$924K | – | 3976 |
|
|
2015
Q2 | $924K | Buy |
29,190
+10,997
| +60% | +$355K | ﹤0.01% | 2763 |
|
|
2015
Q1 | $692K | Sell |
18,193
-15,586
| -46% | -$620K | ﹤0.01% | 2848 |
|
|
2014
Q4 | $1.32M | Buy |
+33,779
| New | +$1.18M | ﹤0.01% | 2625 |
|
|
2014
Q3 | – | Sell |
-22,352
| Closed | -$759K | – | 4483 |
|
|
2014
Q2 | $759K | Sell |
22,352
-101,449
| -82% | -$3.39M | ﹤0.01% | 3182 |
|
|
2014
Q1 | $4.27M | Buy |
+123,801
| New | +$5.59M | 0.01% | 1714 |
|
D.E. Shaw & Co's XLRN Position: Q4 2021 in Review
D.E. Shaw & Co sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 271,291 shares — an estimated $46.7M sold.
D.E. Shaw & Co first reported a position in XLRN in Q1 2014 and held it in 17 quarters. The position peaked at $46.7M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- D.E. Shaw & Co reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- D.E. Shaw & Co sold 271,291 Acceleron Pharma shares in Q4 2021, an estimated $46.7M.
- D.E. Shaw & Co first reported a position in Acceleron Pharma in Q1 2014 and held it in 17 quarters.
- D.E. Shaw & Co's Acceleron Pharma position peaked at $46.7M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.